• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 7:22:44 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELOX alert in real time by email
    SC 13G/A 1 zk2125506.htm SC 13G/A

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)*
     
    Eloxx Pharmaceuticals, Inc.
    (Name of Issuer)

    Common Stock, USD 0.01 par value per share
     (Title of Class of Securities)

    29014R103
    (CUSIP Number)
     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    CUSIP No. 29014R103
    13G
    Page 2 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
     
    Menora Mivtachim Holdings Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
       
     (a) ☐
       
     (b) ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Israel
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    ---
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    2,094,208 (*)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    ---
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    2,094,208 (*)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    2,094,208 (*)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
     
     
    5.22% (*) (**)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (See instructions)
     
     
     
    CO
     
     
     
     

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 40,153,000 Ordinary Shares outstanding as of as of December 31, 2020 (as reported on Bloomberg LP).
     
    2

    Item 1. (a)                Name of Issuer:

    Eloxx Pharmaceuticals, Inc.

                 (b)
    Address of Issuer's Principal Executive Offices:

    950 Winter Street
    Waltham Massachusetts 02451

    Item 2. (a)
    Name of Person Filing:

    Menora Mivtachim Holdings Ltd.

    (b)
    Address of Principal Business Office:

    Menora Mivtachim Holdings Ltd. – Menora House, 23 Jabotinsky St., Ramat Gan 5251102, Israel

    (c)
    Citizenship or Place of Incorporation:

    Menora Mivtachim Holdings Ltd. – Israel

    (d)
    Title of Class of Securities:

    Common Stock, USD 0.01 par value per share

    (e)
    CUSIP Number:

    29014R103

    Item 3.
    Not applicable.

    Item 4.
    Ownership:

    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.

    As of December 31, 2020, the securities reported herein were beneficially owned as follows:


    •
    1,795,364 shares of common stock (representing 4.47% of the total shares of common stock outstanding) beneficially owned by Menora Mivtachim Pensions and Gemel Ltd.;

    •
    275,425 shares of common stock (representing 0.69% of the total shares of common stock outstanding) beneficially owned by Menora Mivtachim Insurance Ltd.;

    •
    23,419 shares of common stock (representing 0.06% of the total shares of common stock outstanding) beneficially owned by Menora Mivtachim Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd.; and

    3

    The securities reported herein are beneficially owned by Menora Mivtachim Holdings Ltd. ("Menora Holdings") and by entities that are direct or indirect, wholly-owned or majority-owned, subsidiaries of Menora Holdings (the "Subsidiaries"), such as Menora Mivtachim Insurance Ltd., Shomera Insurance Company Ltd., Menora Mivtachim Pensions and Gemel Ltd., and Menora Mivtachim Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd.   The economic interest or beneficial ownership in a portion of the securities covered by this report (including the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities) is held for the benefit of insurance policy holders or the members of provident funds or pension funds, as the case may be.  This statement on Schedule 13G shall not be construed as an admission by Menora Holdings or by any of the Subsidiaries that it is the beneficial owner of any of such securities covered by this statement on Schedule 13G, and each of Menora Holdings and the Subsidiaries disclaims beneficial ownership of any such securities except to the extent of its pecuniary interest therein.

    (b)
    Percent of class:

    See row 11 of cover page of each reporting person

    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person

    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above

    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person

    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    The beneficial ownership of the securities reported herein is described in Item 4(a).

    4

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.


    5

     
    Item 10.                    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    6

     SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 10, 2021
     
       
    Menora Mivtachim Holdings Ltd.

    /s/ Shai Kompel      /s/ Nir Moroz
    By:  Shai Kompel    By:  Nir Moroz
    Title:    CFO             Title:   CIO
     

    7

     
    Get the next $ELOX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELOX

    DatePrice TargetRatingAnalyst
    12/17/2021$4.00Outperform
    Oppenheimer
    11/18/2021$2.00 → $1.00Neutral
    HC Wainwright & Co.
    11/11/2021$3.00 → $2.00Neutral
    HC Wainwright & Co.
    6/30/2021$3.10Buy
    Mizuho
    More analyst ratings

    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00

      12/17/21 5:45:41 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

      11/18/21 6:16:16 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously

      11/11/21 6:39:05 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      11/19/24 4:01:28 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      10/17/24 4:01:29 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      8/14/24 4:01:27 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

      Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w

      11/12/24 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

      First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene

      7/11/24 11:46:35 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

      ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI

      4/16/24 7:30:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:02:21 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Androski Lindsay was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:56 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rubin Steven D was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:36 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

      Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp

      10/17/23 8:00:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

      SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc

      6/1/23 9:10:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Eloxx Pharmaceuticals Announces Changes to Board of Directors

      Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.

      7/5/22 8:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

      SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      8/20/24 8:13:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/13/23 4:52:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/14/22 6:18:22 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Financials

    Live finance-specific insights

    See more
    • Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

      Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d

      9/14/22 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

      ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise

      11/17/21 7:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE

      4/1/21 7:45:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care